利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

15 条记录 (耗时 0.013 秒)

    PHARMACEUTICAL COMBINATION COMPRISING ATORVASTATIN DERIVATIVES
    2.
    发明申请
    PHARMACEUTICAL COMBINATION COMPRISING ATORVASTATIN DERIVATIVES 审中-公开
    包含ATORVASTATIN衍生物的药物组合

    公开(公告)号：WO2007054789A1

    公开(公告)日：2007-05-18

    申请号：PCT/IB2006/003152

    申请日：2006-11-08

    申请人： RANBAXY LABORATORIES LIMITED ,  SATTIGERI, Jitendra A. ,  BANSAL, Vinay S.

    发明人： SATTIGERI, Jitendra A. ,  BANSAL, Vinay S.

    IPC分类号： A61K31/4025 ,  A61K31/40

    CPC分类号： C07D207/34 ,  A61K31/397 ,  A61K31/40 ,  A61K31/4025 ,  A61K31/44 ,  A61K31/4439 ,  A61K31/445 ,  A61K31/47 ,  A61K31/554 ,  A61K31/70 ,  A61K45/06 ,  C07D405/06 ,  A61K2300/00

    摘要： This invention relates to a combination product or medicament comprising at least one novel substituted pyrrole derivative and one or more dyslipidemic agents, antiobesity agents, antihyperglycaemic agents, anti-inflammatory agents or mixture thereof. Also provided herein are the pharmaceutical compositions comprising at least one novel substituted pyrrole derivative and one or more dyslipidemic agents, antiobesity agents, antihyperglycaemic agents, anti-inflammatory agents or mixture thereof and optionally together with at least one pharmaceutically acceptable carrier, and methods for the treatment or prophylaxis of cardiovascular diseases, Alzheimer's disease, obesity, diabetes or inflammatory diseases comprising administering to a mammal in need thereof therapeutically effective amounts of combination pharmaceutical composition comprising at least one novel substituted pyrrole derivative and one or more dyslipidemic agents, antiobesity agents, antihyperglycaemic agents, anti-inflammatory agents or mixtures thereof.

    摘要翻译： 本发明涉及包含至少一种新的取代的吡咯衍生物和一种或多种血脂异常剂，抗肥胖剂，抗高血糖药，抗炎剂或其混合物的组合产品或药物。 本文还提供了包含至少一种新的取代的吡咯衍生物和一种或多种血脂变剂，抗肥胖剂，抗高血糖药，抗炎剂或其混合物以及任选地与至少一种药学上可接受的载体的药物组合物，以及用于 治疗或预防心血管疾病，阿尔茨海默氏病，肥胖症，糖尿病或炎性疾病，包括向有需要的哺乳动物施用治疗有效量的组合药物组合物，其包含至少一种新的取代的吡咯衍生物和一种或多种血脂异常剂，抗肥胖剂，抗高血糖药 药剂，抗炎剂或其混合物。

    PROCESS FOR THE PREPARATION OF ATORVASTATIN
    5.
    发明申请
    PROCESS FOR THE PREPARATION OF ATORVASTATIN 审中-公开
    制备ATORVASTATIN的方法

    公开(公告)号：WO2005118536A1

    公开(公告)日：2005-12-15

    申请号：PCT/IB2005/001526

    申请日：2005-05-31

    申请人： RANBAXY LABORATORIES LIMITED ,  SATTIGERI, Jitendra, A. ,  SALMAN, Mohammad ,  RAWAT, Shobhana ,  SETHI, Sachin

    发明人： SATTIGERI, Jitendra, A. ,  SALMAN, Mohammad ,  RAWAT, Shobhana ,  SETHI, Sachin

    IPC分类号： C07D207/34

    CPC分类号： C07D207/34

    摘要： The invention relates to processes for the preparation of atorvastatin. Atorvastatin is known by the chemical name [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid. The hemi-calcium salt of atorvastatin is useful as an inhibitor of the enzyme 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMG-CoA reductase). The invention also relates to pharmaceutical compositions that include the atorvastatin or a pharmaceutically acceptable salt thereof and to use of said compositions for treating hypolipidemia, hypocholesterolemia and atherosclerosis.

    摘要翻译： 本发明涉及制备阿托伐他汀的方法。 阿托伐他汀以化学名称[R-（R *，R *）] -2-（4-氟苯基） - ，δ-二羟基-5-（1-甲基乙基）-3-苯基-4 - [（苯基氨基 ）羰基] -1H-吡咯-1-庚酸。 阿托伐他汀的半钙盐可用作3-羟基-3-甲基戊二酰辅酶A还原酶（HMG-CoA还原酶）的抑制剂。 本发明还涉及包含阿托伐他汀或其药学上可接受的盐以及所述组合物用于治疗低脂血症，低胆固醇血症和动脉粥样硬化的药物组合物。

    ANTIDIABETIC AGENTS
    8.
    发明申请
    ANTIDIABETIC AGENTS 审中-公开
    抗菌剂

    公开(公告)号：WO2005058813A2

    公开(公告)日：2005-06-30

    申请号：PCT/IB2004/004143

    申请日：2004-12-15

    申请人： RANBAXY LABORATORIES LIMITED ,  SATTIGERI, Jitendra A. ,  SALMAN, Mohammad

    发明人： SATTIGERI, Jitendra A. ,  SALMAN, Mohammad

    IPC分类号： C07D

    CPC分类号： C07D417/10

    摘要： Provided herein are alkynyl derivatives, which have PPAR agonist activity, and can be used as antidiabetic compounds. Compounds disclosed herein can be used for the treatment of diabetes and diabetes-associated complications, to diseases and conditions in which insulin resistance is a pathophysiological mechanism, and to diseases or conditions such as Type II diabetes, dyslipidaemia, hypertension, coronary heart disease, cardiovascular disease, atherosclerosis, nephrosclerosis, polycystic ovarian syndrome, eating disorders, diabetes nephropathy, glomerulonephritis, glomerularsclerosis, nephrotic syndrome, psoriasis, obesity or dementia. Compounds disclosed herein also can inhibit aldose reductase. Processes for the preparation of disclosed compounds, pharmaceutical compositions containing the disclosed compounds, and methods for treating diabetes mellitus and diseases and conditions mediated through insulin resistance are provided.

    摘要翻译： 本文提供具有PPAR激动剂活性的炔基衍生物，并且可用作抗糖尿病化合物。 本文公开的化合物可用于治疗糖尿病和糖尿病相关并发症，其中胰岛素抵抗是病理生理学机制的疾病和病症，以及诸如II型糖尿病，血脂异常，高血压，冠心病，心血管疾病 疾病，动脉粥样硬化，肾硬化，多囊卵巢综合症，进食障碍，糖尿病肾病，肾小球性肾炎，肾小球硬化症，肾病综合征，牛皮癣，肥胖或痴呆。 本文公开的化合物还可以抑制醛糖还原酶。 提供了制备所公开化合物的方法，含有所公开化合物的药物组合物，以及治疗糖尿病的方法以及通过胰岛素抵抗介导的疾病和病症。